EOM 1352: Fri 7 June 2024, 11:36

Current Edition

ramusmedical
Europe

Surgery with ultrasound treats high blood pressure in trial

A minimally invasive surgical procedure that targets nerves leading to the kidneys could one day offer a safe way for some people to reduce their blood pressure med...
Continue Reading →
Europe

Aimmune’s peanut drug moves closer to European market

An experimental peanut allergy drug from Aimmune Therapeutics has met the primary endpoint of a Phase 3 European study, according to topline data released by the com...
Continue Reading →
news

Conatus drug misses goal, hitting NASH stocks

Conatus Pharmaceuticals on Thursday disclosed its lead liver disease drug emricasan missed its primary goal in a Phase 2b study of patients with non-alcoholic steato...
Continue Reading →
Asia Pacific

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabet...
Continue Reading →
news

PCI Announces Expansion of High Potent Tableting and Powder Modification Capacity

Investment in new technologies at PCI’s global manufacturing Center of Excellence in Tredegar, Wales, to double highly potent tableting capacity and boost powder han...
Continue Reading →
news

PCI Pharma Services Appoints New Chief Financial Officer, SVP, Serge Dupuis

Philadelphia, PA – 22 March, 2019. Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to welcome Serge Dupuis as Sen...
Continue Reading →
news

Researchers report promising results of potential reversal agent

In patients with acute coronary syndromes, coronary artery stenting, or a history of prior heart attacks, antiplatelet therapy can be lifesaving. Ticagrelor, in comb...
Continue Reading →
news

Apple heart study: Early proof of concept, or a bit of a gimmick?

Preliminary results in a study of Apple Watch's ability to track heart data found 0.5%, or 2,161 people, received notifications of a potential irregular heartbeat an...
Continue Reading →
news

Lilly’s Cyramza comes up positive in first-line lung cancer trial

Eli Lilly's anti-angiogenic therapy Cyramza met the primary endpoint of a late-stage study, improving progression-free survival in previously untreated patients with...
Continue Reading →
news

Pfizer, Merck KGaA scrap yet another Bavencio ovarian cancer trial

Pfizer and Merck KGaA are dismantling their second phase 3 ovarian cancer study for Bavencio since December. Pfizer and Merck KGaA have had a rough go at broaden...
Continue Reading →
Quotient